Burak W - Search Results

1

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL. Ramaswamy B, et al. Among authors: burak w. Breast Cancer Res Treat. 2005 Sep;93(1):67-74. doi: 10.1007/s10549-005-3784-z. Breast Cancer Res Treat. 2005. PMID: 16184461 Clinical Trial.

2

Patterns of recurrence after sentinel lymph node biopsy for breast cancer.

Badgwell BD, Povoski SP, Abdessalam SF, Young DC, Farrar WB, Walker MJ, Yee LD, Zervos EE, Carson WE 3rd, Burak WE Jr. Badgwell BD, et al. Ann Surg Oncol. 2003 May;10(4):376-80. doi: 10.1245/aso.2003.07.026. Ann Surg Oncol. 2003. PMID: 12734085

3

Trends in breast cancer presentation and care according to age in a single institution.

Agnese DM, Yusuf F, Wilson JL, Shapiro CL, Lehman A, Burak WE Jr. Agnese DM, et al. Am J Surg. 2004 Oct;188(4):437-9. doi: 10.1016/j.amjsurg.2004.06.029. Am J Surg. 2004. PMID: 15474444

4

Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias?

Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Woodard S, et al. Cancer. 2003 Sep 15;98(6):1141-9. doi: 10.1002/cncr.11640. Cancer. 2003. PMID: 12973837 Free article.

5

Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase.

Burak WE Jr, Quinn AL, Farrar WB, Brueggemeier RW. Burak WE Jr, et al. Breast Cancer Res Treat. 1997 May;44(1):57-64. doi: 10.1023/a:1005782311558. Breast Cancer Res Treat. 1997. PMID: 9164678

6

Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients.

Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE Jr. Saha S, et al. Among authors: burak we jr. J Surg Oncol. 2000 Mar;73(3):134-7. doi: 10.1002/(sici)1096-9098(200003)73:3<134::aid-jso4>3.0.co;2-f. J Surg Oncol. 2000. PMID: 10738265

7

Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer.

Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, Carson WE, Yee LD, Agnese DM, Pozderac RV, Hall NC, Farrar WB. Povoski SP, et al. Among authors: burak we. Ann Surg Oncol. 2006 Nov;13(11):1412-21. doi: 10.1245/s10434-006-9022-z. Epub 2006 Sep 7. Ann Surg Oncol. 2006. PMID: 16957969 Clinical Trial.

8

Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer.

Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ, Carson WB, Burak WE Jr. Abdessalam SF, et al. Among authors: burak we jr. Am J Surg. 2001 Oct;182(4):316-20. doi: 10.1016/s0002-9610(01)00719-x. Am J Surg. 2001. PMID: 11720662

9

Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Lustberg MB, et al. Among authors: burak w. J Thorac Oncol. 2010 May;5(5):713-8. doi: 10.1097/JTO.0b013e3181d7776d. J Thorac Oncol. 2010. PMID: 20354452 Free PMC article. Clinical Trial.

10

Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin.

Burak WE Jr, Goodman PS, Young DC, Farrar WB. Burak WE Jr, et al. J Surg Oncol. 1997 Jan;64(1):27-31. doi: 10.1002/(sici)1096-9098(199701)64:1<27::aid-jso6>3.0.co;2-r. J Surg Oncol. 1997. PMID: 9040797 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters